UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Num ...

Dr. Reddy's Laboratories (RDY) announced entering into a license and supply agreement with Iceland-based partner, Alvotech (ALVO) , for the commercialization of AVT03. AVT03, a human monoclonal antibody, is Alvotech's biosimilar candidate to Amgen's Prolia and Xgeva (denosumab). Both Prolia and Xgeva are currently approved to treat various indications, including osteoporosis in postmenopausal women and prevention of skeletal-related events in adults with advanced malignancies. The collaboration agreement se ...

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ET Company Participants Richa Periwal - Head of Investor Relations GV Prasad - Co-Chairman and Managing Director Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Neha Manpuria - Bank of America Merrill Lynch Kunal Dhamesha - Macquarie Capital Securities Saion Mukherjee - Nomura Securities Tarang Agrawal - Old Bridge Capital Tushar Manudhane - Motilal Os ...

Company Participants Conference Call Participants Operator I now hand the conference over to Ms. Richa Periwal. Thank you, and over to you, Ma'am. Thank you. A very good morning and good evening to all of you and thank you for joining us today for the Dr. Reddy's earnings conference call for the quarter ended, December 31, 2023. Earlier during the day, we've released our results and the same was also posted on our website. This call is being recorded and the playback and transcript shall be made available o ...

Dr ReddyÂ's Laboratories Ltd (NYSE:RDY) Q2 2024 Earnings Conference Call October 27, 2023 10:00 AM ET Company Participants Richa Periwal - IR Parag Agarwal - CFO Erez Israeli - CEO Conference Call Participants Mikaela Franceschina - Barclays Bank Kunal Dhamesha - Macquarie Research Neha Manpuria – Bank of America Merrill Lynch Gagan Thareja - ASK Investment Managers Aman Vij - Astute Investment Management Damayanti Kerai - HSBC Surya Patra - PhillipCapital Saion Mukherjee - Nomura Securities Tushar Manudhan ...

All amounts in millions, except EPS 7 Computation of capital employed 8 Conference Joining Information | --- | --- | --- | |-------------------------------------------------------------------------|-------------------------------------|-------------| | Option 2: Join through below Dial-In Numbers \nUniversal Access Number: | +91 22 6280 1219 \n+91 22 7115 8120 | | | | | | | | USA: 1 866 746 2133 | | | International Toll Free | UK: 0 808 101 1573 | | | Number: | Singapore: 800 101 2045 | | | | Hong Kong: | 8 ...

Dr Reddy's Laboratories Ltd (NYSE:RDY) Q1 2024 Earnings Conference Call July 26, 2023 10:00 AM ET Conference Call Participants Ladies and gentlemen, good day and welcome to the Dr. Reddy's Q1 FY '24 Earnings Call. [Operator Instructions]. Thank you Darwin. Thank you. A very good morning and good evening to all of you and thank you for joining us today for the Dr. Reddy's earnings conference call for the quarter ended June 30, 2023. Earlier during the day we have released our results and the same is also pos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (cid:0) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR (cid:0) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2023 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR (cid:0) SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

Exhibit 99.1 Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com June 12, 2023 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ) BSE Limited (Scrip Code: 500124) Dear Sirs, Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Sche ...

Dr Reddy's Laboratories Ltd (NYSE:RDY) Q4 2023 Earnings Conference Call May 10, 2023 10:00 AM ET Company Participants Richa Periwal - IR Gunupati Prasad - Co-Chairman Parag Agarwal - CFO Erez Israeli - CEO Conference Call Participants Balaji Prasad - Barclays Bank Surya Patra - PhillipCapital Damayanti Kerai - HSBC Cyndrella Carvalho - JM Financial Ankush Mahajan - Axis Securities Nitin Agarwal - DAM Capital Advisors Madhav Marda - FI Industries Tushar Manudhane - Motilal Oswal Financial Services Kunal Dham ...